Circumventing Resistance to Kinase-Inhibitor Therapy
- 15 June 2006
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 354 (24), 2594-2596
- https://doi.org/10.1056/nejme068073
Abstract
Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer research and therapy, ranging from the identification of the first specific chromosomal abnormality associated with cancer to the development of imatinib as a specific, targeted therapy for the disease.1 In this issue of the Journal, two articles2,3 continue this tradition by describing how an understanding of resistance to imatinib has led to a strategy for circumventing resistance. These articles — one concerning nilotinib and the other dasatinib — are of fundamental importance for at least three reasons. First, they provide immediate hope for patients in whom CML . . .Keywords
This publication has 11 references indexed in Scilit:
- Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 2006
- Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALLNew England Journal of Medicine, 2006
- Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with ImatinibClinical Cancer Research, 2005
- Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell, 2005
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Imatinib as a Paradigm of Targeted TherapiesAdvances in Cancer Research, 2004
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaCancer Cell, 2002
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000